Click here to visit Vernalis plc
Page 5 of 6
Vernalis plc announces today that the US Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding the New Drug Application (NDA) for CCP-07.
For more information on Vernalis, click below to download a copy of our fact sheet
T: 1-484-913-0700 F: 1-610-651 5976Contact informationMaps and directionsContact form
To report SUSPECTED ADVERSE REACTIONS, contact Vernalis Therapeutics, Inc. at 1-855-705-9546 and email@example.com or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch